NCT04040673

Brief Summary

Ex vivo vibrational spectroscopy (VS), including Raman spectroscopy (RS) of thyroid tissue samples, collected from patients undergoing routine diagnostic thyroid biopsies for diagnosis of potential thyroid cancer. Raman spectra are to be correlated with consensus histopathology and clinical outcomes. Multivariate analysis to be used to evaluate the classification accuracy of VS ex vivo.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 29, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 1, 2019

Completed
4.8 years until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

February 26, 2024

Status Verified

February 1, 2024

Enrollment Period

1 year

First QC Date

July 29, 2019

Last Update Submit

February 23, 2024

Conditions

Keywords

cancerRamanthyroid

Outcome Measures

Primary Outcomes (1)

  • Test the Raman needle probe on freshly exised tissue

    Measure Raman spectra and match with histopathology. Perform leave-one-out analysis to measure performance of diagnosis of Raman spectroscopy

    1 year

Secondary Outcomes (1)

  • Calculate diagnostic performance of Raman spectroscopy probe for thyroid cancer

    1 year

Study Arms (5)

Normal benign

participants with normal benign nodules (no cancer)

Procedure: thyroid lobectomyDevice: Raman spectroscopy probe measurement

Follicular thyroid cancer

participants with follicular thyroid cancer

Procedure: thyroid lobectomyDevice: Raman spectroscopy probe measurement

Papillary thyroid cancer

participants with papillary thyroid cancer

Procedure: thyroid lobectomyDevice: Raman spectroscopy probe measurement

Anaplastic thyroid cancer

participants with anaplastic thyroid cancer

Procedure: thyroid lobectomyDevice: Raman spectroscopy probe measurement

Medullary thyroid cancer

participants with medullary thyroid cancer

Procedure: thyroid lobectomyDevice: Raman spectroscopy probe measurement

Interventions

routine surgical removal of thyroid for biopsy

Also known as: thyroid nodule removal
Anaplastic thyroid cancerFollicular thyroid cancerMedullary thyroid cancerNormal benignPapillary thyroid cancer

The measurement of Raman spectra from the excised tissue

Anaplastic thyroid cancerFollicular thyroid cancerMedullary thyroid cancerNormal benignPapillary thyroid cancer

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients attending for routine diagnostic biopsy

You may qualify if:

  • Patients undergoing routine diagnostic thyroid biopsy at surgery

You may not qualify if:

  • Patients are unable to provide informed consent.
  • Patients not attending for standard diagnostic biopsy for thyroid cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Biophotonics Research Unit

Gloucester, Gloucestershire, GL1 2AF, United Kingdom

Location

Related Publications (5)

  • Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H, Benson CB, Doubilet PM, Cibas ES, Barletta J, Cho N, Gawande A, Ruan D, Moore FD Jr, Pou K, Larsen PR, Alexander EK. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab. 2013 Feb;98(2):564-70. doi: 10.1210/jc.2012-2968. Epub 2012 Dec 28.

    PMID: 23275525BACKGROUND
  • Jenkins CA, Lewis PD, Dunstan PR, Harris DA. Role of Raman spectroscopy and surface enhanced Raman spectroscopy in colorectal cancer. World J Gastrointest Oncol. 2016 May 15;8(5):427-38. doi: 10.4251/wjgo.v8.i5.427.

    PMID: 27190582BACKGROUND
  • Feng X, Moy AJ, Nguyen HTM, Zhang J, Fox MC, Sebastian KR, Reichenberg JS, Markey MK, Tunnell JW. Raman active components of skin cancer. Biomed Opt Express. 2017 May 4;8(6):2835-2850. doi: 10.1364/BOE.8.002835. eCollection 2017 Jun 1.

    PMID: 28663910BACKGROUND
  • Crow P, Barrass B, Kendall C, Hart-Prieto M, Wright M, Persad R, Stone N. The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines. Br J Cancer. 2005 Jun 20;92(12):2166-70. doi: 10.1038/sj.bjc.6602638.

    PMID: 15928665BACKGROUND
  • Rau JV, Fosca M, Graziani V, Taffon C, Rocchia M, Caricato M, Pozzilli P, Onetti Muda A, Crescenzi A. Proof-of-concept Raman spectroscopy study aimed to differentiate thyroid follicular patterned lesions. Sci Rep. 2017 Nov 2;7(1):14970. doi: 10.1038/s41598-017-14872-1.

    PMID: 29097686BACKGROUND

MeSH Terms

Conditions

Thyroid DiseasesThyroid NeoplasmsNeoplasms

Condition Hierarchy (Ancestors)

Endocrine System DiseasesEndocrine Gland NeoplasmsNeoplasms by SiteHead and Neck Neoplasms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Post-Doctoral Research Fellow

Study Record Dates

First Submitted

July 29, 2019

First Posted

August 1, 2019

Study Start

June 1, 2024

Primary Completion

June 1, 2025

Study Completion

June 1, 2025

Last Updated

February 26, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Pathology reports will be linked using a pseudo-anonymous unique study identifier

Locations